Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05467917 · ClinicalTrials.gov registry record
ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases
A clinical trial of COVID-19 and SARS CoV 2 Infection, sponsored by Columbia University.
- Active
- Registry status
- 374
- Enrollment target
- 1
- Study location
NCT05467917: Active study of COVID-19 and SARS CoV 2 Infection, sponsored by Columbia University.
NCT05467917 is a study of COVID-19 and SARS CoV 2 Infection that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 374 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05467917, a study of COVID-19 and SARS CoV 2 Infection, is active but no longer recruiting, sponsored by Columbia University.
- ACTIVE NOT RECRUITING
- Registry status
- 374 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this project is to understand the household level transmission dynamics and factors that predict transmission of SARS-COV-2 between pediatric and adults in the household. The novel coronavirus SARS-CoV-2 has spread all around the world and testing has posed a challenge globally. Not much is known about who does and does not acquire SARS-CoV2. It is also unknown who will show symptoms or progress severe disease or death from COVID-19. Children tend to have milder symptoms or none at all. Therefore, few children have ever been tested, so it is unknown if they get the infection as much as anyone else. Health care providers are highly exposed, and they do not get tested unless they show severe symptoms. If groups like children and health workers are infected, they can unknowingly spread SARS-CoV-2, unless they practice behaviors like self-isolation very strictly. The investigators aim to measure the prevalence of SARS-CoV-2 in children and health care workers at a large urban health center. The investigators will also measure how many people in the household of the positive children and health care workers also get SARS-CoV-2 infection. Lastly, the investigators will see what other risk factors affect who acquires SARSCoV-2 from inside or outside of the household clusters.
Primary Outcome
Period prevalence of SARS-CoV-2 infection as detected by use of home nasal swab and blood samples. At home nasal swab every 48-72 hours for about 15 days, with another potential collection on day 21 and day 28 of the study. Blood sample collected at enrollment and at day 28.
Conditions Studied
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 374 participants |
| Start Date | 2021-08-01 |
| Est. Completion | 2026-03 |
What the registry record for NCT05467917 still lists
NCT05467917 is an observational study that tracks outcomes without assigning an intervention. The registered 374 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.
NCT05467917 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05467917 about?
NCT05467917 is a clinical study titled "ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases". The goal of this project is to understand the household level transmission dynamics and factors that predict transmission of SARS-COV-2 between pediatric and adults in the household. The novel coronavirus SARS-CoV-2 has spread all around the world and testing has posed a challenge globally. Not muc...
What is the current status of trial NCT05467917?
This trial is currently active not recruiting. The enrollment target is 374 participants. The study started on 2021-08-01. Estimated completion is 2026-03.
What conditions does trial NCT05467917 study?
This clinical trial studies the following conditions: COVID-19, SARS CoV 2 Infection, Households.
Who is sponsoring clinical trial NCT05467917?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05467917 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05467917's enrollment target sits among peer trials
374 127th of 298 higher than 172 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI